CD86 and prostate cancer: The majority of the studies provided information for the following surrogate markers: CD14 (prostate cancer 8/17 studies, RCC 7/12 studies), HLA-DR (prostate cancer 11/17, RCC 7/12), CD86 (prostate cancer 11/17, RCC 8/12), and CD83 (prostate cancer 9/17, RCC 9/12).